Aardvark Therapeutics Announces FDA Orphan Drug Designation Granted to ARD-101, a Novel Drug Candidate for Prader-Willi Syndrome

The FDA granted Aardvark Therapeutics a Rare Pediatric Designation for the use of ARD-101 in Prader-Willi Syndrome (PWS), a rare genetic disease characterized by extreme and unabating hunger. Aardvark’s Phase 2 trial of oral ARD-101 in young adults with PWS is now open for enrollment of additional subjects. Click here to view the full article (external link)

The release as fetched from its publisher. aardvarktherapeutics.com ↗